Will eyedrops replace injections for Macular Degeneration?

Researchers at the University of Birmingham have created a new eyedrop that can deliver wet macular degeneration treatment to the back of the eye. Macular degeneration causes damage to the retina at the back of the eye so this is why it is necessary for the medication to be focused on that area rather than […]

Discontinuing macular degeneration injections results in vision loss

A retrospective, observational study examined the data from 35 patients who had received anti-VEGF injections of the eye for treatment of the wet form of macular degeneration but then stopped treatment despite continued symptoms. Researchers found a notable deterioration in visual acuity over two years. Researchers looked at the best-corrected visual acuity (BCVA) at the […]

Doctors successful retinal stem cell treatment

Doctors successfully transplanted retinal stem cells from a donor to the recipient in the first ever surgery of its type. Previously, doctors had performed a retinal stem cell transplant back in 2014 using that patient’s own skin cells that were reprogrammed. That procedure was considered a success after a year with no decline in the patient’s […]

Eye injections increase glaucoma risk

Patients who receive seven or more Intravitreous eye injections of bevacizumab (Avastin) each year are at a higher risk of eventually needing glaucoma surgery according to study results recently published in the JAMA Ophthalmology medical journal. Intravitreous injections are the standard therapy for patients suffering from the wet form of macular degeneration. Researchers examined data […]

App allows users to ‘see’ retinal disease

A new virtual and augmented reality app called “In My Eyes” allows users to experience what it is like to have different kinds of retinal disease. Regeneron Pharmaceuticals teamed with Intouch Solutions to create the app. Available for free download in the iTunes and Google app stores, the app can be used with or without […]

Testing of drug underway for patients with wet macular degeneration

A new drug that is currently being tested on mice and rabbits requires fewer injections than the current standard intravitreal therapy for age-related macular degeneration (AMD). Researchers are hopeful that injections in humans would have a longer-lasting effect: several months between injections instead of every four to six weeks. The new drug lasted two months […]

Macular Degeneration may Start in Gut

Researchers at the University of Montreal examined how bacterial flora in the intestinal tract may influence the risk of developing the wet (neovascular) form of macular degeneration. Wet AMD is characterize by the formation and leakage of new and weak blood vessels in the eye. Obesity is one of the five most common factors related […]

Protein responsible for retinal aging

Researchers at the University of Wisconsin-Madison have discovered that a protein known as Transmembrane 135 (Tmem135) is responsible for retinal aging. Mutations of Tmem135 causes age-related retinal disease including age-related macular degeneration. Using lab mice that matched similar retinal abnormalities that are found in mice that have early onset of retinal disease, the researchers mapped […]

Warning for stroke patients with wet AMD

Patients suffering from wet macular degeneration who have had a stroke are being warned against using bevacizumab (Avastin®) within a 6 month period after the stroke. This is because people who had a bevacizumab eye injection within 3 to 6 months after a stroke had a significantly higher mortality rate than patients who did not receive injections. […]

Visual acuity not maintained with anti-VEGF

A follow-up study was conducted to determine the long-term benefit and visual acuity outcomes of patients undergoing anti-VEGF treatments, such as Eyelea, Lucentis and Avastin. What researchers found was that visual gains were not maintained after 5 years of injections. Records of 647 patients with wet AMD were analyzed in the Comparison of Age-Related Macular […]